Development of DH-I-180-3 loaded lipid nanoparticle for photodynamic therapy.

Photodynamic therapy (PDT) is a promising noninvasive treatment modality for cancer. Photosensitizer and specific wave length of light are the key component of PDT. DH-I-180-3, a second generation photosensitizer, was incorporated into lipid nanoparticle for simultaneous fluorescent imaging and targeting therapy. Solid lipid nanoparticle (SLN) and nanostructured lipid carriers (NLC) based on poloxamer 188 as surfactant and lecithin as co-surfactant were prepared using solvent evaporation and hot homogenization technique. Stearic acid and Capmul(®) MCM C8 were utilized as solid lipid and liquid lipid, respectively. The particle size of SLN and NLCs was around 200 nm and decreased when a part of stearic acid was replaced with Capmul(®) MCM C8. Drug loading efficacy was significantly enhanced when the percentage amount of liquid lipid increased. All the polydispersity indices of the SLN/NLCs were below 0.3, and displayed a narrow particle size distribution. Zeta potentials of all the lipid nanoparticles were below -30 mV, maintaining sufficient repulsive force and achieving enhanced physical stability. No significant change in the particle size and polydispersity index was observed from lyophilized SLN/NLCs. When the photocytotoxic effects of the formulations were evaluated in MCF-7 cells, GI 50 of SLN was less than half of DH-I-180-3 solution, and NLCs containing either 5 or 15%w/w of Capmul(®) MCM C8 exerted higher cytotoxicity than SLN. The fluorescence microscope images displayed enhanced cellular accumulation of DH-I-180-3 loaded in SLN and NLCs, which was closely correlated with the photocytotoxicity results. It was concluded that the incorporation of DH-I-180-3 into the nanoparticles enhanced their targeting efficacy and improved photocytotoxicity.

Synthesized Pheophorbide a-mediated photodynamic therapy induced apoptosis and autophagy in human oral squamous carcinoma cells.

BACKGROUND: Pheophorbide a (Pa) is a chlorine-based photosensitizer derived from an ethnopharmacological herb, and our group recently synthesized Pa by the removal of a magnesium ion and a phytyl group from chlorophyll-a. In this study, the effect of photodynamic therapy (PDT) with synthesized Pa was examined in a human oral squamous cell carcinoma (OSCC) cells. METHODS: Cells were treated with PDT with Pa, and reactive oxygen species (ROS) and mitochondrial membrane potential [ΔΨ (m)] were examined. Apoptosis was measured using annexin V staining and immunoblot. Autophagy was characterized by the increase in LC3B-II and the formation of autophagosome and acidic vesicular organelles (AVOs). RESULTS: Pa-PDT inhibited the proliferation of OSCC cells in a dose-dependent manner. Pa-PDT increased the number of apoptotic cells by inactivating ERK pathway. Pa-PDT also induced autophagy in OSCC cells evidenced by the increased levels of LC3 type II expression and the accumulation of AVOs. The inhibition of autophagy enhanced Pa-PDT-mediated cytotoxicity through an increase in necrosis. CONCLUSIONS: These results suggest that synthesized Pa-PDT exerts anti-tumor effects by inducing apoptosis and autophagy and provide novel evidence that Pa-PDT induces autophagy, and autophagy inhibition enhances Pa-PDT-mediated necrosis in OSCC cells.

Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1.

The transition from a chemotherapy-responsive cancer to a chemotherapy-resistant one is accompanied by increased expression of multidrug resistance 1 (MDR1, p-glycoprotein), which plays an important role in the efflux from the target cell of many anticancer agents. We recently showed that a Forkhead box-containing protein of the O subfamily 1 (FoxO1) is a key regulator of MDR1 gene transcription. Because nuclear localization of FoxO1 is regulated by silent information regulator two ortholog 1 (SIRT1) deacetylase, we wondered whether SIRT1 dominates MDR1 gene expression in breast cancer cells. Overexpression of SIRT1 enhanced both FoxO reporter activity and nuclear levels of FoxO1. Protein expression of MDR1 and gene transcriptional activity were also up-regulated by SIRT1 overexpression. In addition, SIRT1 inhibition reduced both nuclear FoxO1 levels and MDR1 expression in doxorubicin-resistant breast cancer cells (MCF-7/ADR) cells. A potent SIRT1 inhibitor, amurensin G (from Vitis amurensis), was identified by screening plant extracts and bioassay-guided fractionation. The compound suppressed FoxO1 activity and MDR1 expression in MCF-7/ADR cells. Moreover, pretreatment of MCF-7/ADR cells with 1 µg/ml amurensin G for 24 h increased cellular uptake of doxorubicin and restored the responsiveness of MCF-7/ADR cells to doxorubicin. In xenograft studies, injection of 10 mg/kg i.p. amurensin G substantially restored the ability of doxorubicin to inhibit MCF-7/ADR-induced tumor growth. These results suggest that SIRT1 is a potential therapeutic target of MDR1-mediated chemoresistance and that it may be possible to develop amurensin G as a useful agent for chemoresistance reversal.

(-)-Epigallocatechin-3-gallate inhibits invasion and migration of salivary gland adenocarcinoma cells.

(-)-Epigallocatechin-3-gallate (EGCG) has inhibitory effect on a variety of cancers by inducing apoptosis and cell cycle arrest or inhibiting angiogenesis and metastasis. EGCG has been found to induce apoptosis in salivary gland carcinoma cells, however, it is not known whether EGCG affects invasion and migration. Thus, this study was performed to clarify whether EGCG affects invasion and migration of salivary gland tumors. Matrigel invasion assay, wound scratch assay and migration assay using commercial kit were performed. beta1 integrin expression and activation of its downstream molecules such as focal adhesion kinase (FAK), AKT and extracellular signal-regulated kinase (ERK) were examined by Western blot. Enzymatic activity of matrix metalloprotease (MMP)-2 and MMP-9 was examined by gelatin zymography. EGCG inhibited effectively invasion and migration of SGT cells in a dose-dependent manner. EGCG also inhibited the activation of beta1 integrin-downstream molecules such as FAK, AKT and ERK as well as the expression of beta1 integrin itself. Moreover, MMP-2 and MMP-9 expression and their enzymatic activity were reduced by EGCG in a dose-dependent manner. These results indicate that EGCG may effectively suppress salivary gland tumors by inhibiting metastasis through beta1 integrin-mediated signaling.

Expression of amino acid transporter LAT1 and 4F2hc in the healing process after the implantation of a tooth ash and plaster of Paris mixture.

BACKGROUND: In order to elucidate the expression pattern of L-type amino acid transporter 1 (LAT1) in the bone formation process, the expressions of LAT1 and its subunit 4F2 heavy chain (4F2hc) were investigated in the healing process after the implantation of a tooth ash-plaster of Paris mixture in rats with calvarial osseous defect. MATERIALS AND METHODS: Circular calvarial defects (8 mm in diameter) were made midparietally. The rats were divided into 2 groups, 1 control group and 1 experimental group. In the control group, the defect was only covered with a soft tissue flap (control group); in the experimental group, it was filled with a mixture of tooth ash and plaster of Paris (2:1 by weight; mixture group). The rats were sacrificed at 1, 2, 4 and 8 weeks after operation and RT-PCR and immunohistochemical analyses were performed. RESULTS: In the RT-PCR analysis, the expressions of the LAT1 and 4F2hc mRNAs were slightly stronger in the experimental group than in the control group. In the immunohistochemical analysis, at 1 week after operation, the LAT1 protein and its subunit 4F2hc protein were mainly expressed in the osteoblasts, osteocytes and interstitial tissues of the area around the defect and the inner part of newly forming bone in both groups. The expressions of LAT1 and 4F2hc proteins were decreased at 2 and 4 weeks after operation. The LAT1 and 4F2hc proteins were scarcely expressed at 8 weeks after operation in both groups. The expressions of LAT1 and 4F2hc proteins were slightly stronger in the mixture group than in the control group. CONCLUSION: These results suggest that the LAT1 and its subunit 4F2hc are highly expressed in the early stage of new bone formation and may have an important role in providing cells with neutral amino acids, including several essential amino acids, at that stage.